Panaeolus

Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research

Retrieved on: 
火曜日, 4月 23, 2024
Psilocybin, Genetics, Psilocybe, ITS, Genomics, CTAB, AGC, Panaeolus, Partnership, Health Canada, Research, KPU, Single-nucleotide polymorphism, DNA, SNP, FRA

VANCOUVER, British Columbia, April 23, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, is thrilled to announce an innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre (KPU-AGC).

Key Points: 
  • VANCOUVER, British Columbia, April 23, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, is thrilled to announce an innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre (KPU-AGC).
  • Optimi boasts an extensive genetic bank of over 200 psilocybin-containing mushroom strains, making it among the largest globally.
  • Chase, Chief Science Officer at Optimi, expressed enthusiasm for the partnership and its potential impact on mushroom science and research.
  • "The Kwantlen Polytechnic University Applied Genomics Centre brings a wealth of experience and expertise in genomics research, making it an ideal partner for Optimi’s innovative initiatives in mushroom science,” he added.

Optimi Health Completes Largest Legal Natural Psilocybin Harvest in Canadian History

Retrieved on: 
木曜日, 9月 8, 2022
MDMA, EU, CSE, Safety, Psilocybin, Research, PTSD, Biomass, Special access program, BLUE, Botany, Anxiety, API, Health Canada, Depression, GLOBE, Company, Medication, FRA, Industry, Health, Patient, Â, Fungiculture, Pharmaceutical industry, Psilocybe, Panaeolus, Agriculture

VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) (Optimi or the Company), is pleased to announce that it has completed what it believes to be the largest legal natural psilocybin harvest in Canadian history.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) (Optimi or the Company), is pleased to announce that it has completed what it believes to be the largest legal natural psilocybin harvest in Canadian history.
  • The Company is licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances, most notably MDMA, as well as functional mushrooms that focus on the health and wellness markets.
  • All Optimi mushroom products are grown from the Companys world-leading psilocybin genetic bank and are grown in EU-GMP compliant clean rooms that ensure sterile cultivation and undergo almost 300 different analytical tests post-harvest.
  • All surplus inventory from the harvest will be safely stored in Optimis Level 8 Security Vault to ensure minimal degradation of the natural psilocybin.

Optimi Health Unveils Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients

Retrieved on: 
水曜日, 8月 10, 2022
Serenity, Psilocybin, Death, Interview, Special access program, GLOBE, Phrase, Form, Clinical trial, Cancer, Sale, Biomass, SAP, Panaeolus, Drug prohibition law, Patient, Family, Health Canada, FRA, Controlled Substances Act, Blister, EU, Research, Anxiety, News, CSE, Time, Medicine, Health, FOR, Pharmaceutical industry, Mobile phone, Public relations, Risk management, Cultivation

VANCOUVER, British Columbia, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic formulations for transformational human experiences, is celebrating the launch of Blue Serenity, Canada’s first natural therapeutic psilocybin product, in collaboration with psilocybin patient advocate Thomas Hartle.

Key Points: 
  • Once approved by health authorities under Canadas Special Access Program (SAP) or an authorized clinical trial, patients, doctors, and researchers will receive Blue Serenity in blister packs of eight (8) psilocybin capsules.
  • Blue Serenity is packaged according to current regulations and guidelines governing the manufacture and commercial distribution of medical/pharmaceutical products (EU-GMP).
  • We are tremendously excited to be partnering with Thomas to become the first Canadian company to launch a natural psilocybin product specifically to help patients seeking relief through the Special Access Program, he added.
  • Further, Ciprick confirmed that proceeds from the sale of Blue Serenity will directly benefit psilocybin patients through Hartles new charity, a venture that will provide access to psilocybin therapy for underserved adults.